Category: In the News

Presented at the 24th Congress of the European Hematology Association (EHA), Promedior, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 2 study of PRM-151 in myelofibrosis (MF) patients who were ineligible for Ruxolitinib or had failed the drug. Promedior looks forward to advancing the clinical program for PRM-151 in both MF and will explore other fibrotic indications in the future. PRM-151 demonstrated promising antifibrotic activity as measured by a reduction in bone marrow fibrosis and improvement in hematologic measures. According to Dr. Srdan Verstovsek, Professor, Leukemia Department, MD Anderson Cancer Center. "Patients also showed a reduction in their myeloproliferative neoplasm symptoms, as well as a trend to prolonged survival with PRM-151 monotherapy in these refractory MF patients with great unmet need."  Click here to read the full release ...

Today the American Society of Clinical Oncology is wrapping up their 2019 ASCO meeting held annually in Chicago, IL. Although ASCO does not focus solely on blood cancers, the MPN Research Foundation looks forward to attending each year to discuss the status of MPN research and treatments with oncology professionals, drug companies, and fellow advocacy groups. Click the links below to read the abstracts and updates pertaining to MPN related science that was presented at ASCO 2019. ASCO 2019 Abstracts, Posters, Meeting Videos, and SlidesInterim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis PatientsFedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. Stay tuned. The next conference with MPN news and updates will be at the annual American Society of Hematology conference in December 2019. ...

DATE: 25th to 27th October 2019LOCATION: LISBON, PORTUGAL Dear MPN AN advocate’s, Our Learn Share & Grow approach that can be achieved through collaboration and is the cornerstone for the advancement of MPN knowledge for our members.  The MPN Horizons conference is dedicated to the development of our members as patient advocates and deals with topics such as Psycho-Social issues, How MPN’s work on a Molecular level, how to be an effective Advocate, Pipeline for treatment and Living with an MPN. Dealing with these types of questions is the essence of Learn. Share & Grow and our conference offers the opportunity to support and facilitate the quality of education. This one of a kind conference also provides opportunities to be able to exchange ideas, interact & share best practice and provide a platform to start networking across borders, build alliances and so much more for you to bring back to your own organization.  The registration process will start on June 1, 2019, and we will inform you as soon as...

The 2018 global conference for MPN Patient Advocates was held from August 31st to September 2nd in Prague, the Czech Republic The event consisted of over 20 talks, covering updates on MPN Research, current and emerging therapies, symptom management and a variety of advocacy and support topics. Videos and slides from the presentations are available here. ...

  MPN Horizons 2017 was a great success!  Please take the opportunity to view the video's of all the sessions, and the power point slides that accompany each session. http://www.mpn-advocates.net/mpn-horizons-2017-session-slides-and-videos/   Please look back to our website for information on MPN Horizons 2018.  Information will be posted about next years conference in May 2018!  We look forward to seeing you then!      ...

The first global conference for MPN Patient Advocates was held from November 11th – 13th 2016 in Belgrade, Serbia. Patient advocates attended from Australia, Azerbaijan, Belgium, Brazil, Canada, Chile, Denmark, Finland,  Germany, Hungary, Israel, Italy, Japan, the Netherlands, Norway, Poland, Serbia, Spain, Slovakia, Slovenia, Sweden,  Switzerland, the UK and the USA. The event consisted of over 20 talks, covering updates on MPN Research, current and emerging therapies, symptom management and a variety of advocacy and support topics. Read more about the conference....

Having been founded by patient representatives from the Netherlands, Spain and the UK, the network now has representation from countries all over the world: Organisations that have recently joined are: Flute of Light in Israel, the Canadian MPN Network, the MPN Research Foundation based in the US, ALTE-SMP in France, mpn-netzwerk in Germany, AIL in Italy and new groups from Begium and Switzerland. If you represent MPN patients and agree with our goal to establish international collaboration, please contact us to become member. See our members page....